Phase I study of indicine N-oxide in patients with advanced cancer

Keyphrases

• Phase I Study 100%
• Patients with Advanced Cancer 100%
• Prior Chemotherapy 100%
• Toxic Effects 100%
• N-oxides 100%
• Hepatic Dysfunction 100%
• Prior Radiotherapy 100%
• Indicine 100%
• Solid Tumors 50%
• Anemia 50%
• Clinical High Risk 50%
• Close Monitoring 50%
• Leukemia 50%
• Marrow 50%
• Complete Response 50%
• Thrombocytopenia 50%
• Platelet Count 50%
• Partial Response 50%
• Performance Status 50%
• Hematotoxicity 50%
• Nausea 50%
• Maximum Tolerated Dose 50%
• Dose Reduction 50%
• Vomiting 50%
• Leukopenia 50%
• Skin Melanoma 50%
• Repeated Dose 50%
• Ovarian Carcinoma 50%
• Therapeutic Study 50%
• Recommended Dose 50%
• Pyrrolizidine Alkaloids 50%
• Short Infusion 50%
• Repeated Course 50%
• Ayurvedic Medicine 50%
• Heliotropium Indicum 50%

Medicine and Dentistry

• Advanced Cancer 100%
• Patient History of Chemotherapy 100%
• Toxicity 100%
• Liver Dysfunction 100%
• Patient History of Radiotherapy 100%
• Indicine N Oxide 100%
• Solid Malignant Neoplasm 50%
• Malignant Neoplasm 50%
• Anemia 50%
• Infusion 50%
• Platelet 50%
• Thrombocytopenia 50%
• Leukemia 50%
• Medicine 50%
• Drug Dose Reduction 50%
• Krukenberg Tumor 50%
• Leukopenia 50%
• Nausea and Vomiting 50%
• Repeated Drug Dose 50%
• Recommended Drug Dose 50%
• Melanoma 50%
• Pyrrolizidine Alkaloid 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Advanced Cancer 100%
• Patient History of Chemotherapy 100%
• Toxicity 100%
• Liver Dysfunction 100%
• Patient History of Radiotherapy 100%
• Indicine N Oxide 100%
• Malignant Neoplasm 50%
• Anemia 50%
• Thrombocytopenia 50%
• Leukemia 50%
• Maximum Tolerated Dose 50%
• Solid Malignant Neoplasm 50%
• Ovary Carcinoma 50%
• Melanoma 50%
• Leukopenia 50%
• Nausea and Vomiting 50%
• Pyrrolizidine Alkaloid 50%
• Heliotropium 50%